Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
AZOR 5/20 |
| Manufacturer |
|
Daiichi-Sankyo |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Calcium channel blocker + angiotensin II receptor blocker. |
| Generic Name |
|
Amlodipine (as besylate) 5mg, olmesartan medoxomil 20mg; tabs. |
| Also |
• AZOR 10/20
• AZOR 10/40
• AZOR 5/40
|
| Indications |
|
Hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
Not for initial therapy. May be substituted for titrated components. Individualize; titrate at 2-week intervals; may increase dose of one or both components if BP not controlled on prior therapy. Max one 10/40 tab daily. |
| Precautions |
|
Correct hypovolemia before starting (may need to reduce diuretic) or monitor closely for hypotension. Severe heart failure (if renal function depends on renin-angiotensin-aldosterone system). Severe obstructive coronary disease. Severe aortic stenosis. Severe hepatic or renal impairment. Renal artery stenosis. Elderly (may need lower initial dose of amlodipine). Pregnancy (Cat.C in 1st trimester, Cat.D in 2nd and 3rd trimesters). Nursing mothers: not recommended. |
| Adverse Reactions |
|
Edema, dizziness; headache, hypotension, rash, pruritus, palpitation, urinary frequency, nocturia, hepatic or renal dysfunction, decreased hematocrit, decreased hemoglobin, hyperkalemia (rare). |
| How Supplied |
|
Tabs—30, 90, 100, 1000 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
